Tegafur/gimeracil/oteracil

Red

Brand Name(s):Teysuno

Indication:Advanced gastric cancer

Rationale:1,2,3

Considered:Jan-11

Review Date:Jan-26

Comments:
Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies

NHS England Nov 2020.

PRAC Safety alert – Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment – lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.